The FDA has approved the HEARLab® Cortical Auditory Evoked Potential Analyzer for marketing! Similar to existing ABR technology, it measures the auditory evoked response of a patient. HEARLab tests a later “potential” than ABR (measures 100-300 ms after the signal instead of 1-3 ms). This both allows it to be used with signals that are more speech like than the very short pips used in ABR measurements, and allows it to be used on patients wearing hearing aids. This is especially useful in measuring the aided auditory signal of patients who are unable to tell the clinician if their hearing aids are functioning, such as infants and person with a disability.
HEARLab® is now available for sale in the United States, Canada, Australia, the European Union, and other countries.